Medicare Benefits Schedule - Item 14247

Extracorporeal photopheresis for the treatment of erythrodermic stage III‑IVa T4 M0 cutaneous T‑cell lymphoma; if

(a) the service is provided in the initial six months of treatment; and

(b) the service is delivered using an integrated, closed extracorporeal photopheresis system; and

(c) the patient is 18 years old or over; and

(d) the patient has received prior systemic treatment for this condition and experienced either disease progression or unacceptable toxicity while on this treatment; and

(e) the service is provided in combination with the use of Pharmaceutical Benefits Scheme‑subsidised methoxsalen; and

(f) the service is supervised by a specialist or consultant physician in the speciality of haematology.

Applicable once per treatment cycle (H)

Fee: $2,158.85 Benefit: 75% = $1,619.15

• Previous - Item 14245
• Next - Item 14249